Search Results for "Aliva Biopharmaceuticals Ablexis"
Original Source: Ablexis, LLC
Ablexis, LLC, was founded in December 2009 based on technology established by Aliva Biopharmaceuticals, Inc. Ablexis is developing the AlivaMab Mouse, an innovative, next-generation transgenic mouse platform intended to provide the foundation for the efficient discovery and development of the next wave of human therapeutic antibodies. Ablexis has filed patent applications covering its core technologies, compositions and utilities for its AlivaMab mice. The co...
Matching Channels
Biopharmaceuticals - news, views, blogs and reports
Biopharmaceuticals are medical drugs (see pharmacology) produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living...
BAC’s CaptureSelect products are affinity ligands and affinity resins created by a proprietary technology based on Camelid-derived single domain antibody fragments for the purification of biop...
Boehringer Ingelheim is a global pharmaceutical company with annual sales of over $16 billion, making it the 10th largest pharmaceutical company in the world based on sales. With bases in 47 c...
Top 50 Biopharma Products 2011
Ronald A. Rader, president of the Biotechnology Information Institute provided Contract Pharma a list of the Top 57 Biopharma Products by 2011 revenues (in millions). Mr. Rader subscribes to the sam...
Matching News
Ablexis Announces Licensing of the AlivaMab Mouse Technology to Another Major Pharmaceutical Company
Ablexis, LLC, a biotechnology company dedicated to developing the AlivaMab Mouse, an innovative platform for discovery of the next generation of breakthrough antibody drugs...
Editorial: Biopharmaceuticals – discovery, development and manufacturing
This Special issue, Biopharmaceuticals – discovery, development and manufacturing is edited by Alois Jungbauer and Klaus Graumann and includes articles on various aspects of the development of bioph...
SMi is proud to present their inaugural conference on Lyophilisation: Freeze-drying in pharmaceuticals & Biopharmaceuticals held on the 25-26 February in London. This conference will provide the perfe...
Kythera Biopharmaceuticals raises $70.4 million in IPO
Kythera Biopharmaceuticals Inc. has raised about $70.4 million in its initial public offering of 4.4 million shares. The Calabasas, Calif., company, which is developing an injectable treatment for dou...
New data from KYTHERA Biopharmaceuticals’ ATX-101 studies on double chin
KYTHERA Biopharmaceuticals, Inc. today announced four abstracts will be presented at the 71st American Academy of Dermatology (AAD) Annual Meeting in Miami Beach, Fla.
Inspiration Biopharmaceuticals and Ipsen Announces New Global Commercialization Agreements
Inspiration Biopharmaceuticals Inc. has announced new license, development and commercialization agreements with its strategic partner, Ipsen.
XTL Biopharmaceuticals buys Proteologics shares
XTL Biopharmaceuticals has acquired 4,620,356 shares of Proteologics from Teva Pharmaceutical for nearly NIS6.5m($1.6m).
Matching PubMed Articles
The cost-effectiveness of biopharmaceuticals: A look at the evidence.
Due to the increasing availability and costs of biopharmaceuticals, policymakers are questioning whether they provide good value relative to other health interventions and many are increasingly relyin...
BACKGROUND: The nature of adverse drug reactions observed post-authorization for biopharmaceuticals differs from that observed for chemically synthesized, small molecules (SMs). However, it remains un...
Separation science is the key to successful biopharmaceuticals.
The impact of economic change, advances in science, therapy and production processes resulted in considerable growth in the area of biopharmaceuticals. Progress in selection of microorganisms and impr...
Process validation in manufacturing of biopharmaceuticals. Third edition.
Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars.
Biologics such as monoclonal antibodies are much more complex than small-molecule drugs, which raises challenging questions for the development and regulatory evaluation of follow-on versions of such...
